Once-daily intranasal corticosteroid that controls hayfever and year-round allergic rhinitis better than antihistamines alone, particularly for nasal congestion
Higher-potency newer-generation corticosteroid licensed from age 6, with paediatric and adult dosing in one product
120-spray pack provides 30 to 60 days of treatment per bottle, with convenient side-actuated lever for one-handed use
UK prescriber-supervised supply with free advice on whether fluticasone furoate suits you or an alternative would work better
Fluticasone Furoate 27.5 micrograms Nasal Spray (Avamys generic) 120 doses is one of the newer intranasal corticosteroids in UK pharmacy. The medicine was developed by GlaxoSmithKline and brought to the UK market as Avamys in 2008.
As a result, fluticasone furoate has features that distinguish it from older intranasal corticosteroids. Specifically, the higher potency and longer tissue residence time enable once-daily dosing while maintaining sustained anti-inflammatory effect.
Fluticasone furoate versus fluticasone propionate
These are two distinct molecules, despite the similar names. The differences matter clinically:
Fluticasone furoate (Avamys, generic): newer molecule with higher receptor binding affinity, longer tissue residence time, once-daily dosing standard, generally available as nasal spray and inhaled formulations (Trelegy Ellipta, Relvar Ellipta)
Fluticasone propionate (Flixonase, generic, Pirinase): older molecule, used clinically since the 1990s, once or twice daily dosing, widely available over the counter (Flixonase, Pirinase) and on prescription, also in combination intranasal sprays (Dymista, with azelastine)
In clinical practice, both work well for allergic rhinitis. Furthermore, the choice between them often comes down to availability, cost, dosing preference, and individual response.
Where intranasal corticosteroids sit in allergy treatment
Multiple international guidelines position intranasal corticosteroids as the most effective single medicine class for allergic rhinitis. These include the ARIA initiative, EAACI, BSACI, and NICE Clinical Knowledge Summaries.
They are particularly effective for moderate to severe symptoms or where nasal congestion is prominent.
How intranasal corticosteroids compare to oral antihistamines
Fluticasone furoate and other intranasal corticosteroids act on the underlying inflammatory process. In contrast, oral antihistamines block only the histamine pathway downstream.
As a result, intranasal corticosteroids are:
More effective for nasal congestion (where antihistamines often underperform)
Comparable or superior for rhinorrhoea, sneezing, and itching
Effective for ocular symptoms of allergic conjunctivitis (despite being a nasal spray, fluticasone furoate has demonstrated benefit for eye symptoms in clinical trials)
Effective for the inflammatory component of the late-phase allergic response, which antihistamines don’t address
The stepped approach to allergic rhinitis
Modern UK practice approaches allergic rhinitis in stages:
Mild intermittent symptoms: trigger avoidance plus oral antihistamine as needed (loratadine, cetirizine, fexofenadine over the counter; bilastine, desloratadine, levocetirizine, rupatadine on prescription)
Severe or refractory symptoms: combination intranasal spray (Dymista: fluticasone propionate + azelastine), or addition of leukotriene receptor antagonist (montelukast, with appropriate caution per MHRA 2019 and 2024 neuropsychiatric warnings)
Allergen-specific immunotherapy: Grazax for grass pollen, Acarizax for house dust mite, Itulazax for tree pollen. This is for severe disease driven by specific allergens
How fluticasone furoate compares to other intranasal corticosteroids
Clinical effects are broadly similar across intranasal corticosteroids at equivalent doses. However, the differences matter for individual patients:
Fluticasone furoate (Avamys, generic): once-daily dosing, paediatric licensing from age 6, prescription only in UK, low systemic exposure
Beclometasone dipropionate (Beconase, generic): twice-daily dosing, oldest established option, available OTC and prescription
Budesonide (Benacort, generic): twice-daily dosing, well-established, preferred INCS in pregnancy where treatment is needed
Triamcinolone acetonide (Nasacort): once-daily dosing, alcohol-free aqueous formulation, available OTC
Mometasone furoate (Nasonex prescription, Clarinaze OTC): once-daily dosing, available OTC and prescription
Fluticasone propionate (Flixonase, Pirinase, generic): once or twice daily, widely used, available OTC
What’s distinctive about fluticasone furoate
Several features distinguish this product from alternatives:
Once-daily dosing: convenient and supports better adherence than twice-daily INCS
High receptor binding affinity: in vitro studies show fluticasone furoate has greater affinity for the glucocorticoid receptor than other intranasal corticosteroids
Long tissue residence time: stays bound to nasal tissue longer, supporting once-daily dosing
Low systemic exposure: minimal absorption after intranasal use, supporting good safety profile
Paediatric licensing from age 6: appropriate for child and adolescent allergic rhinitis with adjusted dosing
Clinical evidence for ocular symptoms: trials have shown fluticasone furoate reduces eye symptoms alongside nasal symptoms
Pharmacy First service inclusion: now part of NHS England’s Pharmacy First service for acute sinusitis (rhinosinusitis), expanding its real-world UK availability
Who fluticasone furoate suits well
This product suits patients who:
Want once-daily dosing for better adherence
Have moderate to severe allergic rhinitis where oral antihistamine alone isn’t enough
Have nasal congestion as a prominent symptom (where antihistamines often underperform)
Are children aged 6 and over with allergic rhinitis
Want a prescription product with strong clinical evidence base
Have struggled with adherence to twice-daily INCS
Have used fluticasone furoate successfully in previous seasons
Have allergic conjunctivitis alongside allergic rhinitis (the ocular symptom benefit is clinically useful)
Who might suit alternatives better
Alternative INCS may suit:
Patients wanting OTC supply for short seasonal cover (Beconase Hayfever Relief, Nasacort, Flixonase, Clarinaze are available OTC)
Pregnant women (budesonide has more extensive pregnancy safety data)
Patients with previous benzalkonium chloride sensitivity (Nasacort uses different preservatives)
Patients with severe allergic rhinitis warranting combination therapy (Dymista provides fluticasone propionate plus azelastine in one spray)
Patients with vasomotor (non-allergic) rhinitis (Beclometasone Aqueous and some other INCS include this indication)
Children under 6 (fluticasone furoate is not licensed under age 6)
Courier Pharmacy supply
Courier Pharmacy supplies fluticasone furoate 27.5 micrograms/spray under prescriber and pharmacist supervision. Our prescriber issues the prescription following an online consultation. Alternatively, you can supply your own prescription from your GP.
Key features and specifications
Active ingredient: fluticasone furoate 27.5 micrograms per metered spray
Form: white suspension nasal spray with side-actuated lever for one-handed use
Container: amber glass bottle in off-white plastic casing with light blue cap, with viewing window for bottle contents
Pack size: 120 actuations per bottle (approximately 30 days at standard adult starting dose, 60 days at maintenance dose; 60 days at paediatric standard dose). Pack sizes of 30 and 60 sprays also available
Licensed indication: treatment of symptoms of allergic rhinitis (seasonal and perennial)
Age licensing: adults, adolescents, and children from age 6
Adult and adolescent dose (12 and over): 2 sprays in each nostril once daily (110 mcg/day total)
Maintenance dose: 1 spray in each nostril once daily (55 mcg/day)
Paediatric dose (6 to 11 years): start 1 spray in each nostril once daily (55 mcg/day); can increase to 2 sprays per nostril if needed
Onset: initial effect 8 to 24 hours; meaningful improvement 2 to 3 days; full effect over 1 to 2 weeks of regular use
Maximum duration of continuous use: no specific maximum, but periodic prescriber review is appropriate for long-term use
Use within: 2 months after first opening
Legal category: Prescription-Only Medicine (POM)
Supplied by: Courier Pharmacy, UK GPhC-registered, with prescriber and pharmacist support
Additional information
Quantity
1 x 120 doses, 2 x 120 doses, 3 x 120 doses
MOJO WISDOM
Take control of your health by understanding your condition and what this medication is doing for you.
READ:
More information about this treatment.
UK-based doctors and pharmacists
Discreet and Confidential
UK-based doctors and pharmacists
Free, Expert Advice
No video link provided.
No video link provided.
UK-based doctors and pharmacists
Free, expert advice
Discrete and confidential
Fast delivery
Giving you trusted clinical advice for over 40 conditions
A UK regulated pharmacy providing safe, effective treatments online since 2014
What is Fluticasone Furoate 27.5 micrograms/spray Nasal Spray (Avamys generic, 120 doses)?
Fluticasone furoate is one of the newer intranasal corticosteroids in UK pharmacy. As a result, it has features that distinguish it from the older intranasal corticosteroids like beclometasone and budesonide. Most importantly, it provides effective allergic rhinitis control with once-daily dosing, making it easier to use consistently than twice-daily alternatives. Furthermore, the lower 27.5 microgram per spray dose reflects the higher potency of fluticasone furoate compared to other intranasal corticosteroids. As a result, smaller doses produce equivalent or superior clinical effects.
At Courier Pharmacy, we believe in treatment that fits the person.
That means matching the intranasal corticosteroid to your situation rather than defaulting to whichever is cheapest. Furthermore, it means honest framing of where fluticasone furoate sits in the modern UK allergy treatment landscape. This page covers what fluticasone furoate is, how it compares to other intranasal corticosteroids, who it suits, and how to use it correctly across adult and paediatric age groups.
Five key takeaways
Fluticasone Furoate 27.5 micrograms/spray Nasal Spray (the active ingredient in Avamys, GlaxoSmithKline) is a UK Prescription-Only Medicine (POM) for the treatment of allergic rhinitis symptoms. It is licensed for adults, adolescents, and children from age 6
Standard adult and adolescent dose: 2 sprays in each nostril once daily (110 micrograms total daily dose). Once symptoms are controlled, you can reduce to maintenance dose of 1 spray per nostril once daily (55 micrograms). Children aged 6 to 11 start at 1 spray per nostril once daily and can increase to 2 if needed
Once-daily dosing is the key clinical advantage over twice-daily intranasal corticosteroids (Beconase beclometasone, Benacort budesonide). As a result, fluticasone furoate suits patients who struggle to maintain consistent twice-daily dosing routines
Fluticasone furoate is a different molecule from fluticasone propionate (the active in Flixonase). Furthermore, the two have distinct chemical properties despite the similar names. Fluticasone furoate has higher receptor affinity and longer tissue residence time
Onset of effect begins within 8 to 24 hours; meaningful symptom improvement over 2 to 3 days; maximum effect over 1 to 2 weeks of regular daily use. Start 1 to 2 weeks before the expected pollen season for best hayfever control. The 120-spray pack provides 30 days at standard adult starting dose, or 60 days at maintenance dose
Why choose Courier Pharmacy for Fluticasone Furoate Nasal Spray
At Courier Pharmacy, our approach starts with a simple idea. Treatment should fit the person, not force the person to fit the system.
Dr Ada Jex-Cori
Our service is shaped by the philosophy of Dr Ada Jex-Cori, our brand pharmacist.
Dr Ada represents the spirit of the pharmacy: evidence-led, community-rooted, and willing to challenge the one-size-fits-all approach to medicine.
She is named in honour of three pioneering women in science: Ada Lovelace, the mathematician and visionary; Sophia Jex-Blake, the first female doctor in the UK who fought the medical establishment; and Gerty Cori, the biochemist and Nobel Prize winner.
In our fictional world of Ethrewell, Dr Ada fights against pharma’s standardised approach to medicine. In the real world, she represents what we stand for. Her view is straightforward: you are not broken. The system is. And we are here to change that.
Honest framing of where fluticasone furoate fits
For patients with moderate to severe allergic rhinitis, particularly where nasal congestion is significant, intranasal corticosteroid is the next step that genuinely changes outcomes.
Fluticasone furoate is one well-established choice within this class. Furthermore, its once-daily dosing and paediatric licensing from age 6 are genuine clinical advantages.
For patients with mild intermittent symptoms easily controlled on as-needed loratadine or cetirizine, we won’t push a more involved treatment. The right answer depends on your symptom pattern.
Treatment that fits, not one-size-fits-all
Most online pharmacies deliver the same protocol to everyone. Courier Pharmacy is different.
We think through your situation: what symptoms you have, what you’ve already tried, what you tolerate well, what fits with your wider life, who in your household needs treatment, and what ages you’re dealing with.
Fluticasone furoate may be the right answer for you. Alternatively, a twice-daily INCS like Beconase or Benacort may suit fine. Furthermore, an OTC option (Nasacort, Flixonase, Clarinaze, Beconase Hayfever Relief) may be more accessible for short seasonal use. Or a combination spray like Dymista may be needed for severe symptoms.
Technique support that actually helps
Most patients are never properly taught how to use intranasal sprays. As a result, most use them in ways that put more medicine on the throat than the nasal lining.
Our pharmacist can talk through correct technique:
Head tilted forward, not back
Aim away from the septum
Gentle breathing in, not deep inhalation
Don’t blow your nose afterwards
Use the side-actuated lever firmly with the bottle upright
Patients with MCAS, CFS, fibromyalgia, or other long-term conditions where allergic symptoms overlap with the broader picture
Patients with hand dexterity issues who benefit from the side-actuated lever design
Older patients with multiple comorbidities and medicines
Coordination with your GP and other care
If you have a GP, allergist, ENT specialist, or other healthcare professional involved in your care, we are happy to coordinate.
Joined-up care across primary care, pharmacy, and specialist services produces better outcomes than fragmented care.
Trust earned, not claimed
We are GPhC-regulated. Furthermore, we ground our content in NHS, NICE, BNF, EMC, BSACI, EAACI, and ARIA guidance.
We will tell you honestly if fluticasone furoate isn’t the right answer for your situation. We’d rather give you the right advice than a quick sale.
How to buy Fluticasone Furoate Nasal Spray from Courier Pharmacy
Fluticasone Furoate Nasal Spray is a UK Prescription-Only Medicine (POM). Therefore, our prescriber issues a prescription following an online consultation. Alternatively, you can supply your own prescription from your GP.
How our service works
Add Fluticasone Furoate Nasal Spray to your basket and complete a quick online consultation. The consultation covers your symptoms, allergic history, what you’ve already tried, current medicines, and relevant medical conditions
Our prescriber reviews your answers to confirm suitability. If the prescriber needs additional information or wants to recommend alternatives, we will get in touch
Once approved, your order is prepared and dispatched discreetly
Free pharmacist support is available before and after your purchase
When alternatives might suit better
If fluticasone furoate isn’t the right product for your situation, we will explain why. Alternatives may include:
Loratadine, cetirizine, or fexofenadine (over the counter) if you haven’t tried these
Bilastine, desloratadine, levocetirizine, or rupatadine (on prescription) for second-line antihistamines
Beconase Hayfever Relief (OTC) for short seasonal cover without prescription
Nasacort triamcinolone (OTC) for once-daily INCS without benzalkonium chloride
Mometasone furoate (Clarinaze OTC or Nasonex prescription) as another once-daily INCS
Fluticasone propionate (Flixonase, Pirinase, generic) as an alternative once-daily INCS available OTC
Beclometasone Aqueous (prescription) if you need the broader licensed indications including vasomotor rhinitis
Benacort budesonide if you’d prefer budesonide (preferred INCS in pregnancy)
Dymista (fluticasone propionate + azelastine combined intranasal spray) for severe symptoms
Nasal saline rinses (Sterimar, NeilMed) as adjunct or first-step approach
Allergen-specific immunotherapy (Grazax, Acarizax, Itulazax) for severe disease driven by specific allergens
Referral to an allergist, immunologist, or ENT specialist for complex presentations
GP appointment if you have features warranting medical assessment
Our community service
Our free fortnightly drop-in clinics at Insomnia, Derby run every other week from 10am to 12pm.
Healthcare shouldn’t only happen when you’re paying for it. We show up, even when it’s free.
We cover allergies, hayfever, chronic urticaria, asthma, MCAS, CFS, fibromyalgia, anaphylaxis, immunotherapy, paediatric allergic conditions, hair loss, men’s health, weight management, and whatever else people bring through the door. No appointment needed, no charge, no pressure.
Active ingredients
Each metered spray delivers:
Fluticasone furoate 27.5 micrograms (active ingredient): a newer-generation synthetic glucocorticoid corticosteroid. Fluticasone furoate has high receptor binding affinity, long tissue residence time, and minimal systemic absorption when used intranasally. As a result, the medicine produces potent local anti-inflammatory effects with very low risk of systemic corticosteroid effects
Excipients
Excipients include:
Benzalkonium chloride 8.25 micrograms per actuation (preservative)
Glucose anhydrous
Dispersible cellulose
Polysorbate 80
Disodium edetate
Purified water
Allergy and sensitivity considerations
Several considerations matter:
Benzalkonium chloride sensitivity: a small minority of patients react with persistent nasal irritation. However, alternative INCS options with different preservative systems exist (such as Nasacort triamcinolone)
Polysorbate 80: can be derived from corn or maize. Therefore, patients with severe corn allergy should be aware
Glucose anhydrous content: small amounts only; not clinically significant for diabetes management
Vegetarian and vegan suitability: synthesis intermediates of animal origin may be used in fluticasone furoate manufacture. As a result, the product may not suit strict vegetarians or vegans
Branded versus generic
Fluticasone furoate is the active ingredient in Avamys (GlaxoSmithKline UK), the originator brand. Avamys is supplied as a white suspension in an amber glass bottle within an off-white plastic casing, with a light blue cap and side-actuated lever.
Generic fluticasone furoate 27.5 micrograms/spray products are starting to appear in the UK as patent protection eases. Furthermore, the active ingredient, concentration, and clinical effect are equivalent between branded and generic versions. However, generic versions are typically more affordable.
Courier Pharmacy supplies the most appropriate version of fluticasone furoate 27.5 micrograms/spray based on availability and value. The active ingredient is identical regardless of whether you receive branded Avamys or a generic equivalent.
Where Fluticasone Furoate fits in allergic rhinitis treatment
Allergic rhinitis affects around 20 to 25% of UK adults. In addition, it affects a substantial proportion of children.
The main trigger patterns
UK allergic rhinitis triggers fall into seasonal and perennial categories:
Tree pollens (March to May): birch, hazel, alder, oak
Grass pollens (May to August): the most common UK trigger
Weed pollens (July to September): nettle, dock, mugwort, ragweed
Perennial triggers (year-round): house dust mite, animal dander, indoor moulds
Why allergic rhinitis matters
The impact goes well beyond annoying symptoms. Specifically, research has shown:
Impaired concentration: studies show reduced exam performance, work productivity, and reaction time
Reduced exercise tolerance: particularly for outdoor activities during pollen season
Quality of life impact: across summer months in seasonal patients, year-round in perennial patients
Asthma exacerbation: in the substantial subset with the "united airway" pattern of combined upper and lower respiratory allergic disease
First-line treatment
For mild intermittent symptoms, start with:
Trigger avoidance where practical: pollen forecast monitoring, keeping windows closed, eye protection outdoors, post-outdoor showering
Oral antihistamine as needed: loratadine, cetirizine, or fexofenadine over the counter; bilastine, desloratadine, levocetirizine, or rupatadine on prescription
For around half of patients with mild symptoms, this is sufficient.
Second-line: antihistamine plus intranasal corticosteroid
This is the standard guideline-recommended approach for most patients with significant allergic rhinitis. Furthermore, fluticasone furoate's once-daily dosing makes it a convenient choice within this approach.
Third-line: combination intranasal spray
For severe or refractory symptoms, consider:
Dymista (fluticasone propionate + azelastine combined intranasal spray): faster onset and additive effect for severe symptoms
Fourth-line: allergen-specific immunotherapy
For severe symptoms inadequately controlled by symptomatic treatment:
Sublingual immunotherapy with Grazax (grass pollen), Acarizax (house dust mite), or Itulazax (tree pollen birch group)
Subcutaneous immunotherapy through specialist allergy clinics
Immunotherapy involves 3 years of daily treatment. Furthermore, it can produce sustained benefit lasting years after the course is completed.
How fluticasone furoate works
Fluticasone furoate is a synthetic glucocorticoid corticosteroid with high topical anti-inflammatory potency.
Receptor-mediated effects
Fluticasone furoate binds with high affinity to the intracellular glucocorticoid receptor. Furthermore, the activated complex enters the cell nucleus and modulates gene transcription.
Consequently, the net effects are:
Reduced production of pro-inflammatory cytokines (IL-4, IL-5, IL-13, TNF-alpha)
Increased production of anti-inflammatory proteins (lipocortin-1, IL-10)
Reduced expression of adhesion molecules that recruit inflammatory cells
Stabilisation of mast cells with reduced histamine and tryptase release
Reduced eosinophil recruitment, activation, and survival in nasal tissue
Reduced T-helper-2 (Th2) lymphocyte activity
Reduced vascular permeability with less tissue oedema and congestion
Reduced mucus production and improved mucociliary clearance
Why this matters clinically
The breadth of action explains why intranasal corticosteroids work across the full symptom spectrum:
Nasal congestion: reduced through decreased vascular permeability and mucosal oedema
Rhinorrhoea: reduced through decreased mucus production
Sneezing and itching: reduced through mast cell stabilisation
Ocular symptoms: fluticasone furoate has clinical trial evidence for reducing eye symptoms alongside nasal symptoms
Late-phase allergic response: the inflammatory component antihistamines don't address
Pharmacokinetics
After intranasal administration, fluticasone furoate acts primarily locally on the nasal mucosa.
Furthermore, the molecule has very low oral bioavailability (less than 0.5%). As a result, the small amount swallowed contributes minimally to systemic exposure. Consequently, clinically significant systemic corticosteroid effects are rare at standard intranasal doses.
Specifically, peak plasma concentrations after a single dose are very low (around 18 picograms/ml in extensive pharmacokinetic studies). Furthermore, the elimination half-life supports once-daily dosing.
Once-daily dosing rationale
Fluticasone furoate's pharmacokinetic profile supports effective once-daily dosing. The high receptor binding affinity and long tissue residence time maintain sufficient nasal mucosal effect across the 24-hour period.
In contrast, older intranasal corticosteroids (beclometasone, budesonide) require twice-daily dosing. Therefore, for patients who struggle with twice-daily schedules, once-daily fluticasone furoate may produce better real-world results through improved adherence.
Why daily regular use matters
The cellular mechanisms of corticosteroid action take hours to days to produce maximum effect. This is fundamentally different from antihistamines, which work within 30 to 60 minutes.
Consequently:
Effect builds over days rather than minutes. Some patients notice benefit within 8 to 24 hours, but maximum effect takes 1 to 2 weeks of regular daily use
Starting 1 to 2 weeks before the expected allergen season produces substantially better symptom control
Used regularly through the season, not just when symptoms flare, maintains the anti-inflammatory effect
Stopping and restarting loses the cumulative anti-inflammatory effect
Many patients stop in the first day or two because they expect immediate effect. As a result, they miss the substantial benefit proper sustained use would have provided.
How to use Fluticasone Furoate Nasal Spray
This summary references the patient information leaflet supplied with the product. For any uncertainty, contact our pharmacist for support.
Adult and adolescent dosing (12 years and over)
Standard starting dose:
2 sprays in each nostril once daily, morning preferred for convenience
Total daily dose: 110 micrograms
Maintenance dose once symptoms controlled:
1 spray in each nostril once daily
Total daily dose: 55 micrograms
Titrate to the lowest dose at which effective control is maintained.
Paediatric dosing (children 6 to 11 years)
Starting dose:
1 spray in each nostril once daily
Total daily dose: 55 micrograms
If symptoms not adequately controlled, increase to:
2 sprays in each nostril once daily (110 micrograms/day) until symptoms controlled
Then reduce back to maintenance 1 spray per nostril once daily
Children under 6: not licensed. Therefore, paediatric allergic rhinitis in this age group should be managed under GP guidance using an alternative paediatric-licensed INCS or other approach.
Older patients
Standard adult dose is appropriate. Furthermore, no specific dose adjustment is needed for age alone.
When to start
For seasonal allergic rhinitis (hayfever), start 1 to 2 weeks before the expected pollen season for your dominant allergen:
Tree pollen sufferers: start in February or early March, ready for the March to May tree pollen season
Grass pollen sufferers (the most common UK pattern): start in mid to late April, ready for May to August
Weed pollen sufferers: start in mid to late June, ready for July to September
For perennial allergic rhinitis, start when symptoms appear or when planned, and continue regularly.
Correct spray technique
Spray technique substantially affects how much medicine reaches the nasal lining. Therefore, getting it right matters.
Follow these steps:
Shake the bottle vigorously for 10 seconds to mix the suspension
Squeeze the sides of the cap and remove
Prime the spray if new or unused for some time. Hold the spray upright, with the nozzle pointing away from your face. Press the side-actuated lever firmly 4 to 6 times until a fine mist appears
Shake the bottle again to ensure mixing
Blow your nose gently to clear it
Tilt your head slightly forward, not back. Tilting back makes the spray run down the throat
Insert the nozzle into one nostril and close the other with a finger
Aim the nozzle toward the outer wall of the nostril, not the septum (the cartilage in the middle)
Press the side-actuated lever firmly once for one spray; press twice for two sprays per nostril if that's your dose
Breathe in gently through the nose while spraying
Repeat for the other nostril
Do not blow your nose immediately after spraying
Wipe the nozzle and replace the cap
If the spray runs down your throat or out of your nostril, adjust your technique. Most commonly, the head is tilted too far back or the nozzle aimed at the septum.
Using the side-actuated lever
The Avamys delivery device has a distinctive side-actuated lever rather than a top-mounted button. This design allows easier one-handed use, particularly helpful for patients with hand dexterity issues.
Hold the bottle with the side window facing you. Furthermore, the window allows you to see when the bottle is running low.
When to expect results
Some patients notice benefit within 8 to 24 hours. Most patients see meaningful improvement within 2 to 3 days. Furthermore, maximum effect typically takes 1 to 2 weeks of regular daily use.
Don't stop in the first few days. The effect builds over time.
How long to use it
For seasonal allergic rhinitis: use through the dominant pollen season, typically 2 to 4 months per year. Continue daily even on lower-pollen days.
For perennial allergic rhinitis: longer-term use is appropriate under prescriber review. Long-term safety of fluticasone furoate is well-established.
If symptoms have not improved after 14 days of regular use, contact our pharmacist or your GP.
Missing a dose
If you miss a dose, take it as soon as you remember. However, if it's nearly time for the next dose, skip the missed one.
Don't double-dose to catch up.
Stopping treatment
Fluticasone furoate can be stopped without a taper. Unlike oral corticosteroids, the very low systemic absorption means no withdrawal effect occurs.
However, symptoms of the underlying allergic rhinitis will return if the medicine was effectively controlling them.
Storage and pack life
Store at room temperature, below 25°C, in the original packaging.
Critical pack life information:
Use the spray within 2 months after first opening
Discard 2 months after first use even if the bottle still contains medicine
Do not refrigerate or freeze
Keep out of sight and reach of children
Warnings and precautions for Fluticasone Furoate Nasal Spray
When not to use
Fluticasone furoate should not be used in:
Patients with known hypersensitivity to fluticasone furoate or any excipient (including benzalkonium chloride)
Patients with active nasal or sinus infections (treat the infection first)
Patients with recent nasal surgery or significant nasal trauma (delay until healing complete)
Patients with untreated active tuberculosis, untreated fungal or bacterial systemic infections, or untreated significant viral infections
Children under 6 years (not licensed for this age group)
When to seek assessment
Several situations warrant medical assessment before or instead of self-treatment:
Severe nasal symptoms with significant facial pain or pressure (possible sinusitis warranting different treatment)
Persistent or recurrent nosebleeds beyond minor amounts
Nasal polyps confirmed or suspected
Loss of sense of smell persistent for weeks
Persistent unilateral symptoms, particularly with blood-stained discharge
Symptoms not responding to standard allergic rhinitis treatment
Pregnancy: limited human data. The SmPC advises that fluticasone furoate should only be used in pregnancy if the expected benefit to the mother is greater than any possible risk to the foetus.
For pregnant patients needing intranasal corticosteroid treatment, budesonide has the most extensive pregnancy safety data. Therefore, it is generally preferred as first-line in pregnancy.
Discuss with your prescriber or midwife if you become pregnant during treatment.
Breastfeeding: should only be considered if the expected benefit to the mother is greater than any possible risk to the child. Furthermore, the very low systemic absorption suggests minimal transfer to breast milk.
Paediatric considerations
In children using intranasal corticosteroids long-term, growth should be monitored periodically. However, growth suppression from intranasal corticosteroids at standard doses is rare and generally clinically insignificant.
Furthermore, the benefit of well-controlled allergic rhinitis typically outweighs the theoretical concern in children needing treatment.
Specifically for fluticasone furoate, paediatric clinical trials have shown growth velocity comparable to placebo at standard doses over 52 weeks of treatment.
Patients with eye conditions
Intranasal corticosteroids have very rarely been associated with raised intraocular pressure (glaucoma) and cataract formation with prolonged use.
However, the risk is much lower than with oral or inhaled corticosteroids. As a result, the concern is mostly theoretical at standard nasal doses.
Patients with established glaucoma or family history should mention this to the prescriber. In addition, periodic eye check-ups are sensible for long-term use.
Nasal effects with continued use
Some patients develop nasal effects with prolonged use:
Epistaxis (nosebleeds): the most common side effect of fluticasone furoate, particularly with continued use beyond 6 weeks. Usually small and self-limiting. Check spray technique (aim away from the septum)
Nasal ulceration: may cause irritation or discomfort; streaks of blood when blowing your nose
Dry nose or mild crusting: usually mild and self-limiting. Nasal saline rinses can help
Persistent or significant nosebleeds: stop the spray and seek pharmacist or GP advice
Nasal septal perforation: very rare. Presents as new nosebleeds, whistling on breathing, or visible perforation
Asthma considerations
Many patients with allergic rhinitis also have asthma (the "united airway" pattern). Treating allergic rhinitis effectively often improves asthma control. Therefore, continue your asthma medicines as prescribed.
Patients using inhaled fluticasone furoate for asthma (Relvar Ellipta, Trelegy Ellipta) alongside intranasal fluticasone furoate should mention this. The total fluticasone furoate exposure is worth flagging, although cumulative effect is generally not clinically significant at standard doses.
Rare reports of bronchospasm and dyspnoea
The Avamys SmPC was updated to include bronchospasm and dyspnoea as adverse effects. As a result, patients with significant asthma should be aware that respiratory symptoms warrant prescriber discussion if they develop or worsen.
Vegetarian, vegan, and allergy considerations
Vegetarians and vegans: synthesis intermediates of animal origin can be used; the product may not be suitable for strict plant-based diets
Corn or maize allergy: polysorbate 80 can be derived from corn
Benzalkonium chloride sensitivity: a small minority of patients have sensitivity; alternative INCS options (such as Nasacort) use different preservatives
Systemic corticosteroid effects
At standard intranasal doses, systemic absorption is very low (oral bioavailability less than 0.5%). As a result, clinically significant systemic effects are rare.
Theoretical concerns (adrenal suppression, cataract, glaucoma, osteoporosis, growth suppression in children) are essentially confined to high doses, prolonged use over many years, or patients on multiple corticosteroid products simultaneously.
Discuss with the prescriber if you are using multiple corticosteroid products.
Side effects of Fluticasone Furoate Nasal Spray
Fluticasone furoate is generally well-tolerated. Furthermore, most side effects are mild and local rather than systemic.
Very common side effects (more than 1 in 10 patients)
Epistaxis (nosebleeds): generally minor; particularly common when used for more than 6 weeks continuously
Common side effects (up to 1 in 10 patients)
Nasal ulceration: irritation or discomfort in the nose; streaks of blood when blowing your nose
Headache
Less common side effects
Sneezing immediately after spraying (usually settles with continued use)
Dry nose or mild crusting
Significant nosebleeds requiring spray to be stopped
Throat irritation
Unpleasant taste sensation transiently after spraying
Rare but more significant side effects
Severe hypersensitivity reactions including anaphylaxis (less than 1 in 1000 patients)
Bronchospasm and dyspnoea (rare)
Nasal septal perforation (very rare; usually associated with pre-existing septal damage or poor technique)
Raised intraocular pressure or glaucoma (very rare at standard intranasal doses)
Cataract (very rare; associated with prolonged use over many years)
Significant systemic corticosteroid effects: adrenal suppression, growth suppression in children (very rare at standard doses)
Significant disturbance of taste or smell
Stop and seek advice if
You develop severe or persistent nosebleeds
You develop new visual symptoms (blurred vision, eye pain, change in vision)
You develop signs of severe allergic reaction (significant swelling, difficulty breathing, severe rash)
You develop persistent significant nasal pain
You develop a whistling sound on breathing through the nose
You develop new or worsening shortness of breath, wheezing, or bronchospasm
Your symptoms are not improving despite 14 days of regular correct use
You develop new persistent loss of smell or taste
Yellow Card reporting
You can report suspected adverse drug reactions to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. Reporting helps build the safety picture for everyone.
Drug interactions with Fluticasone Furoate Nasal Spray
Intranasal fluticasone furoate has a low drug interaction profile. The reason: systemic absorption is very low.
Theoretical interactions worth flagging
Strong CYP3A4 inhibitors: ritonavir, ketoconazole, itraconazole, clarithromycin. Co-administration with ritonavir is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid effects. Other strong CYP3A4 inhibitors should be used cautiously
Other corticosteroid products: combined use of intranasal, inhaled, oral, and topical corticosteroids contributes to cumulative systemic exposure. This is particularly relevant for patients using inhaled fluticasone furoate for asthma (Relvar Ellipta, Trelegy Ellipta) alongside intranasal fluticasone furoate
Not significant interactions
Antihistamines (oral and intranasal): no interaction. In fact, combining INCS with oral antihistamine is standard practice
Asthma medicines: inhaled bronchodilators, leukotriene receptor antagonists, and inhaled corticosteroids are compatible
Most blood pressure medicines, statins, antidepressants, hormonal contraceptives: no significant interaction
PPIs and H2 antagonists: no significant interaction
Most antibiotics: no significant interaction (with the macrolide CYP3A4 consideration above)
Frequently asked questions about Fluticasone Furoate Nasal Spray
What is Fluticasone Furoate Nasal Spray used for?
Fluticasone Furoate Nasal Spray is licensed in the UK for the treatment of symptoms of allergic rhinitis, both seasonal (hayfever) and perennial. Furthermore, it is licensed for adults, adolescents, and children from age 6.
Is fluticasone furoate the same as fluticasone propionate (Flixonase)?
No. Despite the similar names, these are two distinct molecules.
Fluticasone furoate (Avamys, generic) is a newer molecule with higher receptor binding affinity and longer tissue residence time, supporting once-daily dosing. Fluticasone propionate (Flixonase, Pirinase, generic) is an older molecule used since the 1990s. Both work well for allergic rhinitis but they are not interchangeable.
How is fluticasone furoate different from other intranasal corticosteroids?
Both products contain different active ingredients but work through the same anti-inflammatory mechanism. However, fluticasone furoate has distinctive features:
Once-daily dosing (Beconase and Benacort are twice-daily)
Higher receptor binding affinity than older intranasal corticosteroids
Long tissue residence time
Distinctive side-actuated lever delivery device
Clinical evidence for ocular symptom benefit
Paediatric licensing from age 6
How is fluticasone furoate different from antihistamines?
Antihistamines block histamine receptors and reduce histamine-mediated symptoms. In contrast, fluticasone furoate acts on the underlying inflammation.
As a result, fluticasone furoate addresses the full spectrum of symptoms including nasal congestion. The two work through different mechanisms and are complementary.
Furthermore, the combination of regular antihistamine plus intranasal corticosteroid is standard practice for moderate to severe allergic rhinitis.
How quickly does fluticasone furoate work?
Some patients notice benefit within 8 to 24 hours. Most patients see meaningful improvement within 2 to 3 days. Furthermore, maximum effect typically takes 1 to 2 weeks of regular daily use.
When should I start using it for hayfever?
Start 1 to 2 weeks before the expected pollen season for your dominant allergen. For UK grass pollen sufferers (the most common pattern), this means starting in mid to late April.
Starting late means missing the maximum benefit period.
Can I use fluticasone furoate with my antihistamine?
Yes. In fact, combining a regular daily oral antihistamine with fluticasone furoate is standard practice for moderate to severe allergic rhinitis.
Can I use fluticasone furoate with my asthma inhaler?
Yes. Fluticasone furoate is compatible with all standard asthma medicines.
However, patients using inhaled fluticasone furoate for asthma (Relvar Ellipta, Trelegy Ellipta) alongside the nasal spray should flag this to the prescriber. The total fluticasone furoate exposure is worth being aware of.
Can I use fluticasone furoate every day for months?
Yes, under prescriber review.
For perennial allergic rhinitis, longer-term use is appropriate. Furthermore, long-term safety of fluticasone furoate is well-established. Periodic review (every 6 to 12 months) is sensible to confirm ongoing benefit.
Why does fluticasone furoate use a side-actuated lever instead of a button?
The side-actuated lever design allows easier one-handed use. Furthermore, it provides good force application for patients who find pressing a top-mounted button difficult.
Patients with hand dexterity issues from arthritis, neurological conditions, or other causes often find the side-actuated design easier.
Why once daily rather than twice daily?
Fluticasone furoate's pharmacokinetic profile supports effective once-daily dosing. The high receptor binding affinity and long tissue residence time maintain sufficient nasal effect across 24 hours.
This is convenient and supports better adherence than twice-daily INCS like beclometasone or budesonide.
Can children use this spray?
Yes, from age 6 with adjusted paediatric dosing (1 spray per nostril once daily, can increase to 2 if needed). Children under 6 are not licensed.
Can older patients use this spray?
Yes. Standard adult dose is appropriate.
Is fluticasone furoate safe in pregnancy?
Limited human data. The SmPC advises use in pregnancy only if the expected benefit to the mother is greater than any possible risk.
Furthermore, for pregnant patients needing intranasal corticosteroid treatment, budesonide (Benacort) has more extensive pregnancy safety data and is generally preferred.
Discuss with your prescriber or midwife if you become pregnant during treatment.
Can I drive while using fluticasone furoate?
Yes. The spray is non-drowsy and has no or negligible influence on the ability to drive and use machines.
Can I drink alcohol while using fluticasone furoate?
Yes. Alcohol does not significantly interact with intranasal fluticasone furoate.
What if I get nosebleeds?
Mild nosebleeds are the most common side effect of fluticasone furoate, particularly with use beyond 6 weeks. Usually relate to spray technique.
Check that you are aiming the nozzle away from the septum. Furthermore, nasal saline rinses can help with dryness. If nosebleeds are significant or persistent, stop the spray and seek pharmacist or GP advice.
What if fluticasone furoate doesn't work for me?
Give it at least 14 days of regular correct use before deciding.
If it still hasn't helped, options include:
Checking your spray technique with our pharmacist
Switching to a different intranasal corticosteroid
Upgrading to a combination intranasal spray (Dymista)
Adding other adjunct treatments
Pursuing further allergy assessment
Can I stop fluticasone furoate suddenly?
Yes. Intranasal corticosteroids do not require a taper. Furthermore, unlike oral corticosteroids, the very low systemic absorption means there is no withdrawal effect.
However, underlying allergic rhinitis symptoms will return if the medicine was controlling them.
Is fluticasone furoate available as a generic?
Branded Avamys (GlaxoSmithKline) has been the main UK product since 2008. Generic fluticasone furoate 27.5 micrograms/spray products are starting to emerge as patent protection eases.
Furthermore, the active ingredient, concentration, and clinical effect are equivalent between branded and generic versions. Courier Pharmacy supplies the most appropriate version based on availability and value.
How should I store fluticasone furoate?
Store at room temperature, below 25°C, in the original packaging. Do not refrigerate or freeze. Keep out of sight and reach of children.
Critical: use the spray within 2 months after first opening. Discard 2 months after first use even if medicine remains in the bottle.
How do I order Fluticasone Furoate from Courier Pharmacy?
Add the product to your basket on courierpharmacy.co.uk and complete the online consultation. Our prescriber will review your answers and confirm suitability.
Alternatively, you can supply your own prescription from your GP or another prescriber. Free pharmacist support is available before and after your order.
More than a prescription: our community
Healthcare shouldn't only happen when you're paying for it.
Every fortnight we run free drop-in talks and clinics at Insomnia, Derby, from 10am to 12pm. We show up, even when it's free.
Bring a question, bring a friend, bring a stack of bewildering letters from another clinic. We'll sit with you.
We cover allergies, hayfever, chronic urticaria, asthma, MCAS, CFS, fibromyalgia, anaphylaxis, immunotherapy, paediatric allergic conditions, hair loss, men's health, weight management, and whatever else people bring through the door. No appointment. No cost. No pressure. Just real support and treatment that fits.
Disclaimer: This article is for information only and isn't a substitute for personal medical advice. Always speak to a qualified prescriber before starting or changing treatment.
How this content was created
Written by the Courier Pharmacy editorial team and reviewed by a GPhC-registered pharmacist.
The content is grounded in the latest NHS, BNF, and EMC guidance. Furthermore, it draws on the real questions patients bring to our drop-in clinics in Derby.
